celecoxib has been researched along with Adenomatous Polyposis Coli in 42 studies
Adenomatous Polyposis Coli: A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)." | 9.14 | The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010) |
| "Observational studies have found a decreased rate of colorectal cancer in people who regularly took aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs)." | 8.81 | Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001) |
| "HT-29 colon cancer cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and tauro-chenodeoxycholic acid (CDCA), mimicking bile of FAP patients treated with UDCA." | 5.38 | Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. ( Marian, B; Nagengast, FM; Peters, WH; Roelofs, HM; Te Morsche, RH; van Heumen, BW, 2012) |
| "Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP)." | 5.14 | The safety and efficacy of celecoxib in children with familial adenomatous polyposis. ( Ayers, GD; Burke, CA; Church, J; Eagle, C; Half, E; Hasson, H; Hawk, E; Lynch, PM; Patterson, S; Richmond, E; Woloj, M, 2010) |
| "Observational studies have found a decreased rate of colorectal cancer in people who regularly took aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs)." | 4.81 | Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001) |
| "Ursodeoxycholic acid has a limited therapeutic role in functional dyspepsia." | 4.31 | Potential therapeutic benefit of ursodeoxycholic acid in the management of non hepato-biliary upper gastrointestinal disorders. ( Khayyat, YM, 2023) |
| " Twelve patients had 14 desmoid tumors: 7 were treated surgically and 7 medically (these patients received celecoxib and tamoxifen citrate therapy)." | 3.73 | Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. ( Goldman, G; Keidar, A; Klausner, JM; Rabau, M; Strul, H; Tulchinsky, H, 2005) |
| " We used the adenomatous polyposis coli (Apc) mutant Min mouse model to determine whether the selective COX-2 inhibitor celecoxib is effective for adenoma prevention and/or regression, and whether it might be safer than the nonselective NSAID previously shown to be most effective in this model, piroxicam." | 3.70 | The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. ( Cole, CE; Jacoby, RF; Kelloff, G; Lubet, RA; Seibert, K, 2000) |
| " Although celecoxib reduces duodenal polyp density in patients with FAP, its long-term use may increase the risk of cardiovascular events and alternatives need to be explored." | 2.78 | Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial. ( Dees, J; Dekker, E; Kampman, E; Koornstra, JJ; Langers, AM; Mathus-Vliegen, EM; Nagengast, FM; Nagtegaal, ID; Peters, WH; Roelofs, HM; van Heumen, BW; Vink-Börger, ME, 2013) |
| "Treatment with celecoxib for 6 months, with before-treatment and after-treatment videos posted to an intranet with an interactive site for scoring." | 2.78 | Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool. ( Khalaf, R; Levin, B; Lynch, PM; Morris, JS; Posadas, J; Rodriguez-Bigas, MA; Ross, WA; Sepeda, VO; Shureiqi, I; Weber, DM, 2013) |
| "Side effects, such as arrhythmia, angina pectoris, and nervous headache, were observed in the celecoxib 400 mg/d group." | 2.72 | [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. ( Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH, 2006) |
| "Celecoxib was shown to regress colorectal adenomas in familial adenomatous polyposis (FAP) patients relative to placebo." | 2.71 | Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. ( Ayers, GD; Cohen, DS; Half, E; Hawk, ET; Levin, B; Lynch, PM; Morris, JS; Morrow, JD; Sinicrope, FA; Stephens, LC, 2004) |
| "Patients with familial adenomatous polyposis have a nearly 100 percent risk of colorectal cancer." | 2.69 | The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. ( Abbruzzese, J; DuBois, RN; Fujimura, T; Godio, L; Gordon, GB; Hawk, E; Hittelman, WN; Jester, SL; Kelloff, G; King, KL; Levin, B; Lynch, PM; Patterson, S; Phillips, RK; Rodriguez-Bigas, MA; Saunders, B; Schumacher, M; Shen, Y; Sherman, JW; Steinbach, G; Su, LK; Wakabayashi, N; Wallace, MH; Zimmerman, S, 2000) |
| "Mortality in patients with advanced colorectal cancer(CRC) remains high." | 2.42 | COX-2 inhibition and colorectal cancer. ( Dubois, RN; Koehne, CH, 2004) |
| " Epidemiologic data showed that chronic intake of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the incidence of colorectal cancer." | 2.42 | Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. ( Chen, BD; Chou, TH; Chu, AJ, 2004) |
| "Celecoxib is an effective anti-inflammatory, analgesic and antipyretic agent therapeutically utilised in the management of osteoarthritis and rheumatoid arthritis." | 2.41 | Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis. ( Davies, NM; de Leeuw, MA; Gudde, TW, 2001) |
| "Celecoxib levels were significantly lower in polyp tissues than in normal colorectal tissues." | 1.72 | Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis. ( Advani, S; Day, RS; Malek, J; Shureiqi, I; Wei, B; Yang, P; Zuo, X, 2022) |
| "HT-29 colon cancer cells and LT97 colorectal micro-adenoma cells derived from a patient with FAP, were exposed to low dose celecoxib and UDCA alone or in combination with tauro-cholic acid (CA) and tauro-chenodeoxycholic acid (CDCA), mimicking bile of FAP patients treated with UDCA." | 1.38 | Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. ( Marian, B; Nagengast, FM; Peters, WH; Roelofs, HM; Te Morsche, RH; van Heumen, BW, 2012) |
| "Five celecoxib-treated patients experienced 6 serious adverse events with one of these events (rash) considered related to celecoxib." | 1.37 | Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. ( Bülow, S; Castells, A; Church, JM; Eagle, CJ; Gallinger, S; Gutierrez, LP; Huang, K, 2011) |
| "Celecoxib has shown benefit in regressing colorectal adenomas and appears to have some duodenal activity as well." | 1.35 | Chemoprevention with special reference to inherited colorectal cancer. ( Lynch, PM, 2008) |
| " Chronic use of high doses of COX-2 inhibitors may induce side effects, and combining the low doses of agents may be an effective way to increase their efficacy and minimize the side effects." | 1.33 | Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. ( Kopelovich, L; Patlolla, JM; Rao, CV; Reddy, BS; Steele, VE; Swamy, MV, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (61.90) | 29.6817 |
| 2010's | 13 (30.95) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, P | 1 |
| Zuo, X | 1 |
| Advani, S | 1 |
| Wei, B | 1 |
| Malek, J | 1 |
| Day, RS | 1 |
| Shureiqi, I | 2 |
| Khayyat, YM | 1 |
| Kemp Bohan, PM | 1 |
| Mankaney, G | 1 |
| Vreeland, TJ | 1 |
| Chick, RC | 1 |
| Hale, DF | 1 |
| Cindass, JL | 1 |
| Hickerson, AT | 1 |
| Ensley, DC | 1 |
| Sohn, V | 1 |
| Clifton, GT | 1 |
| Peoples, GE | 1 |
| Burke, CA | 3 |
| Benech, N | 1 |
| Walter, T | 1 |
| Saurin, JC | 1 |
| van Heumen, BW | 3 |
| Roelofs, HM | 3 |
| Vink-Börger, ME | 1 |
| Dekker, E | 1 |
| Mathus-Vliegen, EM | 1 |
| Dees, J | 1 |
| Koornstra, JJ | 1 |
| Langers, AM | 1 |
| Nagtegaal, ID | 1 |
| Kampman, E | 1 |
| Peters, WH | 3 |
| Nagengast, FM | 3 |
| te Morsche, RH | 2 |
| Lynch, PM | 8 |
| Ignatenko, NA | 1 |
| Besselsen, DG | 1 |
| Stringer, DE | 1 |
| Blohm-Mangone, KA | 1 |
| Cui, H | 1 |
| Gerner, EW | 1 |
| Pérez-Segura, P | 2 |
| Bodas, A | 1 |
| Sereno, M | 1 |
| Martínez-Amores, B | 1 |
| Olivera, H | 1 |
| Díaz, S | 1 |
| López-Asenjo, JA | 1 |
| Puente, J | 1 |
| Maluenda, C | 1 |
| Díaz-Rubio, E | 1 |
| Ayers, GD | 2 |
| Hawk, E | 3 |
| Richmond, E | 1 |
| Eagle, C | 1 |
| Woloj, M | 1 |
| Church, J | 1 |
| Hasson, H | 1 |
| Patterson, S | 3 |
| Half, E | 2 |
| Tan, VP | 1 |
| Chan, P | 1 |
| Hung, IF | 1 |
| Pang, R | 1 |
| Wong, BC | 1 |
| Huang, K | 1 |
| Gutierrez, LP | 1 |
| Bülow, S | 1 |
| Gallinger, S | 1 |
| Castells, A | 1 |
| Eagle, CJ | 1 |
| Church, JM | 1 |
| Dovizio, M | 1 |
| Tacconelli, S | 1 |
| Ricciotti, E | 1 |
| Bruno, A | 1 |
| Maier, TJ | 2 |
| Anzellotti, P | 1 |
| Di Francesco, L | 1 |
| Sala, P | 1 |
| Signoroni, S | 1 |
| Bertario, L | 1 |
| Dixon, DA | 1 |
| Lawson, JA | 1 |
| Steinhilber, D | 1 |
| FitzGerald, GA | 2 |
| Patrignani, P | 1 |
| Marian, B | 1 |
| Lee, Y | 1 |
| Kim, H | 1 |
| Kim, W | 1 |
| Yoon, JH | 1 |
| Jeong, SH | 1 |
| Jung, Y | 1 |
| Manzano, A | 1 |
| Morris, JS | 2 |
| Ross, WA | 1 |
| Rodriguez-Bigas, MA | 2 |
| Posadas, J | 1 |
| Khalaf, R | 1 |
| Weber, DM | 1 |
| Sepeda, VO | 1 |
| Levin, B | 4 |
| Bauer, WM | 1 |
| Lashner, B | 1 |
| Xiao, Z | 1 |
| Luke, BT | 1 |
| Izmirlian, G | 1 |
| Umar, A | 1 |
| Phillips, RK | 3 |
| Conrads, TP | 1 |
| Veenstra, TD | 1 |
| Greenwald, P | 1 |
| Hawk, ET | 2 |
| Ali, IU | 1 |
| Sinicrope, FA | 1 |
| Morrow, JD | 1 |
| Cohen, DS | 1 |
| Stephens, LC | 1 |
| Koehne, CH | 1 |
| Dubois, RN | 2 |
| Chu, AJ | 1 |
| Chou, TH | 1 |
| Chen, BD | 1 |
| Zielinski, SL | 1 |
| Tulchinsky, H | 1 |
| Keidar, A | 1 |
| Strul, H | 1 |
| Goldman, G | 1 |
| Klausner, JM | 1 |
| Rabau, M | 1 |
| Husøy, T | 1 |
| Knutsen, HK | 1 |
| Cruciani, V | 1 |
| Olstørn, HB | 1 |
| Mikalsen, SO | 1 |
| Løberg, EM | 1 |
| Alexander, J | 1 |
| Raskov, HH | 1 |
| Sheng, JQ | 1 |
| Li, SR | 1 |
| Yang, XY | 1 |
| Zhang, YH | 1 |
| Su, H | 1 |
| Yu, DL | 1 |
| Yan, W | 1 |
| Geng, HG | 1 |
| Grösch, S | 1 |
| Schiffmann, S | 1 |
| Geisslinger, G | 1 |
| Swamy, MV | 1 |
| Patlolla, JM | 1 |
| Steele, VE | 1 |
| Kopelovich, L | 1 |
| Reddy, BS | 1 |
| Rao, CV | 1 |
| Smigel, K | 1 |
| Henney, JE | 1 |
| Steinbach, G | 2 |
| Wallace, MH | 2 |
| Gordon, GB | 2 |
| Wakabayashi, N | 2 |
| Saunders, B | 1 |
| Shen, Y | 2 |
| Fujimura, T | 1 |
| Su, LK | 2 |
| Godio, L | 2 |
| Jester, SL | 1 |
| King, KL | 1 |
| Schumacher, M | 1 |
| Abbruzzese, J | 1 |
| Hittelman, WN | 1 |
| Zimmerman, S | 2 |
| Sherman, JW | 1 |
| Kelloff, G | 3 |
| Jacoby, RF | 1 |
| Seibert, K | 1 |
| Cole, CE | 1 |
| Lubet, RA | 1 |
| Bresalier, RS | 1 |
| Davies, NM | 1 |
| Gudde, TW | 1 |
| de Leeuw, MA | 1 |
| Wullen, B | 1 |
| Mühlhöfer, A | 1 |
| Zoller, WG | 1 |
| North, GL | 1 |
| Chau, I | 1 |
| Cunningham, D | 1 |
| Saunders, BP | 1 |
| Rodrigues-Bigas, M | 1 |
| Sherman, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers[NCT00503035] | Phase 2 | 51 participants (Actual) | Interventional | 2003-08-20 | Completed | ||
| Prevention of Progression of Duodenal Adenomas to Cancer in Patients With Familial Adenomatous Polyposis (FAP)[NCT00808743] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase I Pilot Toxicity/Methods Validation Study of Celecoxib in Genotype-Positive Children With Familial Adenomatous Polyposis[NCT00685568] | Phase 1 | 22 participants (Actual) | Interventional | 2002-11-21 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614] | Phase 2 | 58 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13-HODE colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues (NCT00503035)
Timeframe: Baseline to post 6 months of celecoxib treatment
| Intervention | ng/mg tissue protein (Mean) | |||
|---|---|---|---|---|
| polyps before celecoxib treatment | polyps after celecoxib treatment | Normal: before celecoxib treatment | Normal: after celecoxib treatment | |
| Celecoxib | 14.56 | 18.83 | 23.02 | 20.03 |
PGE2 colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues (NCT00503035)
Timeframe: at the baseline colonoscopy (or sigmoidoscopy in patients who had undergone colectomy) before the initiation of celecoxib, and the follow-up colonoscopy or sigmoidoscopy was performed after celecoxib treatment (month 6)
| Intervention | ng/mg tissue protein (Mean) | |||
|---|---|---|---|---|
| Polyps: before celecoxib treatment | Polyps: after celecoxib treatment | Normal: before celecoxib treatment | Normal: after celecoxib treatment | |
| Celecoxib | 14.71 | 20.62 | 21.48 | 24.99 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
11 reviews available for celecoxib and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; As | 2021 |
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; As | 2021 |
Chemoprevention of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2016 |
Chemoprevention of familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2016 |
Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use.
Topics: Adenomatous Polyposis Coli; Algorithms; Anticarcinogenic Agents; Celecoxib; Clinical Trials as Topic | 2010 |
Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use.
Topics: Adenomatous Polyposis Coli; Algorithms; Anticarcinogenic Agents; Celecoxib; Clinical Trials as Topic | 2010 |
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2012 |
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2012 |
Chemoprevention of colorectal cancer: slow, steady progress.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2003 |
Chemoprevention of colorectal cancer: slow, steady progress.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; | 2003 |
COX-2 inhibition and colorectal cancer.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2004 |
COX-2 inhibition and colorectal cancer.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2004 |
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens | 2004 |
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens | 2004 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2006 |
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas].
Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; | 2006 |
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N | 2006 |
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N | 2006 |
Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
Topics: Absorption; Adenomatous Polyposis Coli; Animals; Arthritis; Celecoxib; Costs and Cost Analysis; Cycl | 2001 |
Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
Topics: Absorption; Adenomatous Polyposis Coli; Animals; Arthritis; Celecoxib; Costs and Cost Analysis; Cycl | 2001 |
Celecoxib as adjunctive therapy for treatment of colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Chemotherap | 2001 |
Celecoxib as adjunctive therapy for treatment of colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Chemotherap | 2001 |
8 trials available for celecoxib and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Celecoxib; Cholagogues and Choleretics; Cycloox | 2013 |
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Celecoxib; Cholagogues and Choleretics; Cycloox | 2013 |
The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Celecoxib; Child; Cohort Studies; Colonic Neoplasms | 2010 |
The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Celecoxib; Child; Cohort Studies; Colonic Neoplasms | 2010 |
Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.
Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Adult; Antineoplastic Agents; Celecoxib; Colorectal | 2013 |
Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool.
Topics: Adenoma; Adenomatous Polyposis Coli; Adolescent; Adult; Antineoplastic Agents; Celecoxib; Colorectal | 2013 |
Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antine | 2004 |
Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antine | 2004 |
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non- | 2006 |
[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Angina Pectoris; Anti-Inflammatory Agents, Non- | 2006 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenas | 2000 |
[Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celeco | 2001 |
[Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis].
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celeco | 2001 |
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; C | 2002 |
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; C | 2002 |
23 other studies available for celecoxib and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis.
Topics: Adenomatous Polyposis Coli; Biological Availability; Celecoxib; Humans; Pyrazoles; Sulfonamides | 2022 |
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis.
Topics: Adenomatous Polyposis Coli; Biological Availability; Celecoxib; Humans; Pyrazoles; Sulfonamides | 2022 |
Potential therapeutic benefit of ursodeoxycholic acid in the management of non hepato-biliary upper gastrointestinal disorders.
Topics: Adenomatous Polyposis Coli; Adult; Celecoxib; Drug Therapy, Combination; Dyspepsia; Humans; Ursodeox | 2023 |
Potential therapeutic benefit of ursodeoxycholic acid in the management of non hepato-biliary upper gastrointestinal disorders.
Topics: Adenomatous Polyposis Coli; Adult; Celecoxib; Drug Therapy, Combination; Dyspepsia; Humans; Ursodeox | 2023 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female | 2017 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female | 2017 |
Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.
Topics: Adenomatous Polyposis Coli; Adult; Aged; Cadherins; Caspase 3; Celecoxib; Cyclooxygenase 2; Duodenal | 2013 |
Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls.
Topics: Adenomatous Polyposis Coli; Adult; Aged; Cadherins; Caspase 3; Celecoxib; Cyclooxygenase 2; Duodenal | 2013 |
Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Biogenic Polyamines; Celecoxib; Chemoprevention; Eflor | 2008 |
Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Biogenic Polyamines; Celecoxib; Chemoprevention; Eflor | 2008 |
Celecoxib in a 12-year-old boy with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Male; Pyrazoles; | 2010 |
Celecoxib in a 12-year-old boy with familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Male; Pyrazoles; | 2010 |
Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; | 2011 |
Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; | 2011 |
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Fe | 2012 |
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Fe | 2012 |
Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cele | 2012 |
Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells.
Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cele | 2012 |
Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenomatous Polyposis Coli; Animals; Aspartic Acid; Cecum; Celecoxib; | 2012 |
Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis.
Topics: 6-Ketoprostaglandin F1 alpha; Adenomatous Polyposis Coli; Animals; Aspartic Acid; Cecum; Celecoxib; | 2012 |
[A new drug approach approved in the USA. Cox-2 inhibitor in intestinal cancer].
Topics: Adenomatous Polyposis Coli; Animals; Apoptosis; Celecoxib; Clinical Trials as Topic; Drug Approval; | 2002 |
[A new drug approach approved in the USA. Cox-2 inhibitor in intestinal cancer].
Topics: Adenomatous Polyposis Coli; Animals; Apoptosis; Celecoxib; Clinical Trials as Topic; Drug Approval; | 2002 |
Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.
Topics: Adenomatous Polyposis Coli; Anticarcinogenic Agents; Blood Proteins; Celecoxib; Clinical Trials, Pha | 2004 |
Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.
Topics: Adenomatous Polyposis Coli; Anticarcinogenic Agents; Blood Proteins; Celecoxib; Clinical Trials, Pha | 2004 |
Despite positive studies, popularity of chemoprevention drugs increasing slowly.
Topics: Adenomatous Polyposis Coli; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarci | 2004 |
Despite positive studies, popularity of chemoprevention drugs increasing slowly.
Topics: Adenomatous Polyposis Coli; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarci | 2004 |
Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Celecoxib; Colectomy; Colorectal Neoplasms; Comorbidi | 2005 |
Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Celecoxib; Colectomy; Colorectal Neoplasms; Comorbidi | 2005 |
Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Celecoxib; Connexin 43; Cyclooxygenase 2; Cyclooxygena | 2005 |
Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts.
Topics: Adenoma; Adenomatous Polyposis Coli; Animals; Celecoxib; Connexin 43; Cyclooxygenase 2; Cyclooxygena | 2005 |
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Apoptosis; Atorvastatin; Caspase 3; Ca | 2006 |
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Apoptosis; Atorvastatin; Caspase 3; Ca | 2006 |
Chemoprevention with special reference to inherited colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Ascorbic | 2008 |
Chemoprevention with special reference to inherited colorectal cancer.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Ascorbic | 2008 |
Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthri | 2000 |
Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthri | 2000 |
From the Food and Drug Administration.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bexarote | 2000 |
From the Food and Drug Administration.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bexarote | 2000 |
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agent | 2000 |
The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agent | 2000 |
Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2000 |
Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2000 |
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Syste | 2002 |
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Syste | 2002 |
Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
Topics: Adenomatous Polyposis Coli; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; | 2002 |
Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
Topics: Adenomatous Polyposis Coli; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; | 2002 |